Cyllene Therapeutics raises €33M Series C

GordonMD Global Investments, Merck Ventures, T. Andera Partners, Bpifrance Investissement and Lamond Ventures are among its backers.

The company develops DNA medicines for severe neurogenic bladder conditions and other neurological diseases.

Funding history

Jul 7, 2026Series C · This round€33M

Biotechnology company discovering and developing antibody therapies for diseases with significant unmet need.

$200MPrivate financing · Oct 23, 2026

Clinical-stage drug developer using AI to select therapeutic assets and guide oncology trials.

$237MSeries E · Oct 23, 2026

Tokyo software company developing sales AI agents, an agent operating platform and consulting services for enterprise sales teams.

¥4.8BSeries C debt second close · Oct 23, 2026

Cognitive Credit provides corporate credit data, financial models and AI analysis tools for investment banks and asset managers.

$40MStrategic growth investment · Oct 22, 2026